Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05050669 · ClinicalTrials.gov registry record
Natural History Study of ENPP1 Deficiency and the Early-onset Form of ABCC6 Deficiency
A clinical trial, sponsored by Inozyme Pharma.
- Completed
- Registry status
- 12
- Enrollment target
NCT05050669 is a clinical trial that has completed, run by Inozyme Pharma. The registered enrollment target is 12 participants.
The verdict
NCT05050669 has completed, sponsored by Inozyme Pharma.
- COMPLETED
- Registry status
- 12 participants
- Enrollment target
Study Summary
The purpose of this prospective study is to characterize the natural history of ENPP1 Deficiency and the early-onset form of ABCC6 Deficiency longitudinally. The study will prospectively gather information about the biochemical, physiological, anatomic, radiographic, and functional manifestations (including patient reported outcomes) of each disease.
Interventions
- OTHER No Intervention for this observational study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-06-28 |
| Est. Completion | 2024-06-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05050669
The ClinicalTrials.gov registry entry for NCT05050669 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inozyme Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No Intervention for this observational study is the first listed.
NCT05050669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05050669 about?
NCT05050669 is a clinical study titled "Natural History Study of ENPP1 Deficiency and the Early-onset Form of ABCC6 Deficiency". The purpose of this prospective study is to characterize the natural history of ENPP1 Deficiency and the early-onset form of ABCC6 Deficiency longitudinally. The study will prospectively gather information about the biochemical, physiological, anatomic, radiographic, and functional manifestations (i...
What is the current status of trial NCT05050669?
This trial is currently completed. The enrollment target is 12 participants. The study started on 2022-06-28. Estimated completion is 2024-06-26.
What interventions are being tested in trial NCT05050669?
The interventions under investigation include: No Intervention for this observational study (OTHER).
Who is sponsoring clinical trial NCT05050669?
This trial is sponsored by Inozyme Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.